Figure 2
From: Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma
The pooled OR from 8 studies, including 400 EC patients and 131 controls.
The pooled OR was 8.39 with 95% CI 4.03–17.45, test for overall effect, Z = 5.69, P < 0.00001.
